by | Jul 3, 2021 | TC VIP
In what Hyderabad-based Bharat Biotech claims is the largest efficacy trial in India across 25 trial sites, the company claims its Covid-19 vaccine Covaxin is 65 per cent effective against the Delta variant. In a pre-print paper that is yet to be peer-reviewed, the...
by CS SURBHI SAXENA | Jun 1, 2021 | TC
As per the press release by PIB, Aarogya Setu has rolled out a feature to update Vaccination Status on the Aarogya Setu App. Here is the step wise explanation of how to update the vaccination status. How to update Vaccination status for SELF: Those who are fully...
by CS SURBHI SAXENA | May 15, 2021 | TC
Under Atma Nirbhar Bharat 3.0 Mission COVID Suraksha was announced by the Government of India, to accelerate the development and production of Indigenous COVID Vaccines. This is being implemented by the Department of Biotechnology, Govt. of India at Biotechnology...
by CS SURBHI SAXENA | May 13, 2021 | TC
The National Regulator of the country, the Drugs Controller General of India (DCGI), after careful examination, has accepted the recommendation of Subject Expert Committee (SEC) and accorded permission to conduct the Phase II/III clinical trial of Covaxin (COVID...
by CS SURBHI SAXENA | Apr 25, 2021 | TC
Bharat Biotech has announced the cost of COVAXIN for State governments and Private Hospitals. It will cost 600 rupees per dose for State Governments and 1200 rupees per dose for Private Hospitals. The price of vaccine for export is 15 to 20 dollars....
